C. Camlin, J. Seeley, L. Viljoen, E. Vernooij, M. Simwinga, Lindsey J Reynolds, R. Reis, R. Plank, J. Orne-Gliemann, N. McGrath, J. Larmarange, G. Hoddinott, Monica Getahun, E. Charlebois, V. Bond
{"title":"Strengthening universal HIV ‘test-and-treat’ approaches with social science research","authors":"C. Camlin, J. Seeley, L. Viljoen, E. Vernooij, M. Simwinga, Lindsey J Reynolds, R. Reis, R. Plank, J. Orne-Gliemann, N. McGrath, J. Larmarange, G. Hoddinott, Monica Getahun, E. Charlebois, V. Bond","doi":"10.1097/QAD.0000000000001008","DOIUrl":null,"url":null,"abstract":"The recent publication of new WHO guidelines, including a call for antiretroviral therapy for everyone diagnosed with HIV regardless of CD4+ cell count and preexposure prophylaxis for people at substantial risk of HIV infection [1], marks an important moment for taking stock of what will be needed to take biomedical HIV prevention approaches to scale, and sustain them. As the author of a recent editorial in The Lancet [2] observes, these guidelines are ‘welcome but ambitious. […] No studies exist that address how such a strategy can be executed on a global scale’ (p. 1420).","PeriodicalId":355297,"journal":{"name":"AIDS (London, England)","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000001008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20
Abstract
The recent publication of new WHO guidelines, including a call for antiretroviral therapy for everyone diagnosed with HIV regardless of CD4+ cell count and preexposure prophylaxis for people at substantial risk of HIV infection [1], marks an important moment for taking stock of what will be needed to take biomedical HIV prevention approaches to scale, and sustain them. As the author of a recent editorial in The Lancet [2] observes, these guidelines are ‘welcome but ambitious. […] No studies exist that address how such a strategy can be executed on a global scale’ (p. 1420).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
